Keith D. Kaufman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Keith D. Kaufman has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Maria Alba
Department of Psychiatry and Mental Health Faculty of Medicine Pontificia Universidad Javeriana Bogotá Colombia
2 shared publications Y. Guan
Merck & Co., Inc. Whitehouse Station NJ USA
2 shared publicationsAlbina V. Golovach
1 shared publicationAlessio Aghemo
1 shared publicationAlma Laura Ladron de Guevara Cetina
1 shared publicationAnna Ludovica Fracanzani
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 23 June 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 79 (4) , 888-897
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
- 23 June 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 79 (4) , 888-897
Top Cited PapersOpen AccessA phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
- 19 June 2013
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 15 (12) , 1101-1110
Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function
Aims: The effects of sitagliptin and pioglitazone, alone and in combination, on α ‐ and β‐cell function were assessed in patients with type 2 diabetes. Methods: Following a 6‐week diet/exercise period, 211 patients with HbA1c of 6.5–9.0% and fasting plasma glucose of 7.2–14.4 mmol/l were randomized (1 :1 :1 : 1) to sitagliptin, pioglitazone, sitagliptin + pioglitazone or placebo. At baseline and after 12 weeks, patients were given a mixed meal followed by frequent blood sampling for measurements of glucose, insulin, C‐peptide and glucagon. Results: After 12 weeks, 5‐h glucose total area under the curve ( AUC ) decreased in all active treatments versus placebo; reduction with sitagliptin + pioglitazone was greater versus either monotherapy. The 5‐h insulin total AUC increased with sitagliptin versus all other treatments and increased with sitagliptin + pioglitazone versus pioglitazone. The 3‐h glucagon AUC decreased with sitagliptin versus placebo and decreased with sitagliptin + pioglitazone versus pioglitazone or placebo. Φ s , a measure of dynamic β‐cell responsiveness to above‐basal glucose concentrations, increased with either monotherapy versus placebo and increased with sitagliptin + pioglitazone versus either monotherapy. The insulin sensitivity index ( ISI ), a composite index of insulin sensitivity, improved with pioglitazone and sitagliptin + pioglitazone versus placebo. The disposition index, a measure of the relationship between β‐cell function and insulin sensitivity, improved with all active treatments versus placebo. Conclusions: Sitagliptin and pioglitazone enhanced β‐cell function (increasing postmeal Φ s ), and sitagliptin improved α ‐cell function (decreasing postmeal glucagon) after 12 weeks in patients with type 2 diabetes. Through these complementary mechanisms of action, the combination of sitagliptin and pioglitazone reduced postmeal glucose more than either treatment alone.
- 19 June 2013
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 15 (12) , 1101-1110
Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function
Aims: The effects of sitagliptin and pioglitazone, alone and in combination, on α ‐ and β‐cell function were assessed in patients with type 2 diabetes. Methods: Following a 6‐week diet/exercise period, 211 patients with HbA1c of 6.5–9.0% and fasting plasma glucose of 7.2–14.4 mmol/l were randomized (1 :1 :1 : 1) to sitagliptin, pioglitazone, sitagliptin + pioglitazone or placebo. At baseline and after 12 weeks, patients were given a mixed meal followed by frequent blood sampling for measurements of glucose, insulin, C‐peptide and glucagon. Results: After 12 weeks, 5‐h glucose total area under the curve ( AUC ) decreased in all active treatments versus placebo; reduction with sitagliptin + pioglitazone was greater versus either monotherapy. The 5‐h insulin total AUC increased with sitagliptin versus all other treatments and increased with sitagliptin + pioglitazone versus pioglitazone. The 3‐h glucagon AUC decreased with sitagliptin versus placebo and decreased with sitagliptin + pioglitazone versus pioglitazone or placebo. Φ s , a measure of dynamic β‐cell responsiveness to above‐basal glucose concentrations, increased with either monotherapy versus placebo and increased with sitagliptin + pioglitazone versus either monotherapy. The insulin sensitivity index ( ISI ), a composite index of insulin sensitivity, improved with pioglitazone and sitagliptin + pioglitazone versus placebo. The disposition index, a measure of the relationship between β‐cell function and insulin sensitivity, improved with all active treatments versus placebo. Conclusions: Sitagliptin and pioglitazone enhanced β‐cell function (increasing postmeal Φ s ), and sitagliptin improved α ‐cell function (decreasing postmeal glucagon) after 12 weeks in patients with type 2 diabetes. Through these complementary mechanisms of action, the combination of sitagliptin and pioglitazone reduced postmeal glucose more than either treatment alone.
- 19 August 2009
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 25 (10) , 2507-2514
Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement
In clinical trials, the degree of glucose lowering with sitagliptin has been correlated with the magnitude of dipeptidyl peptidase-4 (DPP-4) inhibition over 24 h. Previous studies evaluating sitagliptin doses ranging from 25 to 200 mg/day demonstrated that the daily dose of 100 mg provided maximal glucose-lowering efficacy for this compound in patients with type 2 diabetes. However, sitagliptin 200 mg once daily provided numerically greater percent plasma DPP-4 inhibition compared with 100 mg once daily. The purpose of this study was to evaluate whether sitagliptin 200 mg once daily provides greater improvement in glycemic efficacy as assessed by weighted mean glucose (WMG) over 24 h relative to sitagliptin 100 mg once daily and to relate the percent DPP-4 inhibition achieved with these doses to any between-treatment differences in glycemic efficacy. In a double-blind crossover study, patients with type 2 diabetes (fasting plasma glucose [FPG] 130-250 mg/dL) were randomized to one of six treatment sequences over three treatment periods (placebo, sitagliptin 100 mg once daily, or sitagliptin 200 mg once daily). Each of the treatment periods was 7 days in duration, with 28-day washout periods between treatments. After each treatment period, patients underwent blood sampling at various time points over 24 h to determine 24-h WMG. Plasma DPP-4 activity was assessed at trough, 24 h following dosing on day 7; percent DPP-4 inhibition was corrected for sample assay dilution. The 103 randomized patients had a baseline mean FPG of 172 mg/dL. Following a planned interim analysis, the study was stopped because the 24-h WMG values were not different between the sitagliptin doses. Furthermore, a significant carryover effect across periods was observed for FPG; thus, efficacy results from period 1 are presented herein. The 24-h WMG values were significantly (p < 0.01) lower with sitagliptin relative to placebo, but the difference between sitagliptin doses was not significant (p = 0.365). Corrected percent plasma DPP-4 inhibition at trough was not significantly (p = 0.791) different with sitagliptin 200 mg (LS mean [95% CI] 96.9% [90.0, 100.0]) compared with sitagliptin 100 mg (95.6% [88.4, 100.0]). The early termination and the carryover effect described above are limitations to this study. Across sitagliptin doses in this study, the similarity of the 24-h WMG concentrations and the similarity of the corrected DPP-4 inhibition values support prior findings that the maximal glucose-lowering efficacy of sitagliptin is achieved with once-daily dosing of 100 mg. Clinicaltrials.gov: NCT00541229.
- 19 August 2009
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 25 (10) , 2507-2514
Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement
In clinical trials, the degree of glucose lowering with sitagliptin has been correlated with the magnitude of dipeptidyl peptidase-4 (DPP-4) inhibition over 24 h. Previous studies evaluating sitagliptin doses ranging from 25 to 200 mg/day demonstrated that the daily dose of 100 mg provided maximal glucose-lowering efficacy for this compound in patients with type 2 diabetes. However, sitagliptin 200 mg once daily provided numerically greater percent plasma DPP-4 inhibition compared with 100 mg once daily. The purpose of this study was to evaluate whether sitagliptin 200 mg once daily provides greater improvement in glycemic efficacy as assessed by weighted mean glucose (WMG) over 24 h relative to sitagliptin 100 mg once daily and to relate the percent DPP-4 inhibition achieved with these doses to any between-treatment differences in glycemic efficacy. In a double-blind crossover study, patients with type 2 diabetes (fasting plasma glucose [FPG] 130-250 mg/dL) were randomized to one of six treatment sequences over three treatment periods (placebo, sitagliptin 100 mg once daily, or sitagliptin 200 mg once daily). Each of the treatment periods was 7 days in duration, with 28-day washout periods between treatments. After each treatment period, patients underwent blood sampling at various time points over 24 h to determine 24-h WMG. Plasma DPP-4 activity was assessed at trough, 24 h following dosing on day 7; percent DPP-4 inhibition was corrected for sample assay dilution. The 103 randomized patients had a baseline mean FPG of 172 mg/dL. Following a planned interim analysis, the study was stopped because the 24-h WMG values were not different between the sitagliptin doses. Furthermore, a significant carryover effect across periods was observed for FPG; thus, efficacy results from period 1 are presented herein. The 24-h WMG values were significantly (p < 0.01) lower with sitagliptin relative to placebo, but the difference between sitagliptin doses was not significant (p = 0.365). Corrected percent plasma DPP-4 inhibition at trough was not significantly (p = 0.791) different with sitagliptin 200 mg (LS mean [95% CI] 96.9% [90.0, 100.0]) compared with sitagliptin 100 mg (95.6% [88.4, 100.0]). The early termination and the carryover effect described above are limitations to this study. Across sitagliptin doses in this study, the similarity of the 24-h WMG concentrations and the similarity of the corrected DPP-4 inhibition values support prior findings that the maximal glucose-lowering efficacy of sitagliptin is achieved with once-daily dosing of 100 mg. Clinicaltrials.gov: NCT00541229.